Company intelligence / Profile preview
NanoGhost
Netanya, Israelnano-ghost.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NanoGhost has demonstrated in preclinical models that its nanovesicle platform can selectively deliver therapeutics to solid tumors—including brain and pancreatic cancers—crossing the blood-brain barrier, reducing tumor size, and prolonging survival after a single treatment. The technology leverages the natural targeting ability of mesenchymal stem cell membranes to home in on cancerous tissue while carrying diverse therapeutic payloads.
- Therapeutic areas
- Oncology
- Modalities
- Nanovesicle-based therapySmall moleculeDNARNAPeptidesProteins
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Not publicly disclosed as of June 2025.
Beyond the preview
Go deeper on NanoGhost.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoGhost.